Ask AI
ProCE Banner Events

Share

APPlexus Fall 2025

Join us for this live program designed to address educational needs specific to advanced practice providers who care for patients with cancer. These webinars will navigate insights and updates across multiple cancer types and deliver innovative, real-time education to nurse practitioners and physician associates worldwide. Our mission is to bridge knowledge gaps, untangle controversies, and spotlight pivotal data in a digestible and engaging format.

Physician Assistants: 5.00 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 5.00 Nursing contact hours, includes 5.00 hour of pharmacotherapy credits

Who Should Attend

This activity is intended for nurse practitioners, nurses, physician associates, and other healthcare professionals who care for patients with cancer.

Time and location

Saturday, September 20, 2025

8:30 AM - 2:45 PM Eastern Time (ET)

Virtual

Agenda

8:30 AM - 8:35 AM - Welcome and Opening Remarks  

8:35 - 9:35 AM – The APP’s Guide to Patient-Centered Management of BTK Inhibitor Therapy in Lymphoma

9:35 AM - 10:35 AM - The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

10:35 AM - 10:40 AM - Break 

10:40 AM - 11:40 AM - Optimizing CLL/SLL Care: Expert Strategies for APPs to Integrate New Targeted Therapies and Practice-Changing Evidence

11:40 AM - 12:40 PMNonaccredited Educational Session, managed by Clinical Care Solutions, a CEA Company   

12:40 PM - 1:40 PM - The APP’s Guide to Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

1:40 PM - 2:40 PM - Maximizing Efficacy and Minimizing Toxicities with Antibody-Drug Conjugates in Breast Cancer

2:40 PM - 2:45 PM - Summary and Closing Remarks 

CME/CE Info

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Diffuse large B-cell lymphoma (DLBCL).

Target Audience
This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with DLBCL treated with bispecific antibodies. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Explain the mechanism of action of novel bispecific antibody therapies vs other anticancer agents and the role of bispecific antibodies in the treatment of DLBCL
  • Design treatment strategies for the use of bispecific antibodies in R/R DLBCL, based on current indications, consensus guidelines, recent key safety and efficacy data, and patient and disease factors
  • Assess patients for eligibility for ongoing clinical trials and for barriers to and disparities in care that may impact outcomes
  • Apply recommendations to mitigate and manage adverse events associated with bispecific antibody treatment in patients with DLBCL

Optimizing CLL/SLL Care: Expert Strategies for APPs to Integrate New Targeted Therapies and Practice-Changing Evidence

Goal Statement
This activity aims to improve the knowledge, confidence, and skills of APPs who care for patients with CLL/SLL on the latest updates in guideline-directed evidence-based medicine, therapeutic management, and strategies to improve health equity, ultimately improving clinical outcomes.

Target Audience
This activity is intended for APPs and other healthcare professionals caring for patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Explain the differences between targeted agents for CLL/SLL based on their mechanisms of action, efficacy, and adverse event profiles to enhance patient understanding.
  • Assess and manage individualized treatment plans for newly diagnosed or relapsed/refractory CLL/SLL, considering prognostic factors, comorbidities, treatment duration, and toxicity profiles.
  • Implement evidence-based strategies to identify, monitor, and manage adverse events associated with CLL/SLL therapies.
  • Utilize effective communication techniques to engage patients in their care, focusing on recognizing and addressing adverse events, managing drug interactions, and promoting adherence to treatment.

The APP’s Guide to Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Goal Statement
This activity aims to equip oncology APPs with the education, skills, and resources needed to provide optimal care to patients with breast cancer who are receiving or are eligible for CDK4/6 inhibitor therapy.

Target Audience
This activity is intended for community nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who care for patients treated with CDK 4/6 inhibitor therapies.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Effectively mitigate and manage toxicities associated with CDK4/6 inhibitor therapy for patients with HR+/HER2- breast cancer, including recommended dose modification strategies
  • Implement recommended strategies to improve adherence to oral CDK4/6 inhibitor therapy in patients with HR+/HER2- breast cancer
  • Employ effective techniques to address factors leading to early discontinuation of oral anticancer therapy in patients with HR+/HER2- breast cancer

Maximizing Efficacy and Minimizing Toxicities with Antibody-Drug Conjugates in Breast Cancer

Goal Statement
This activity aims to equip oncology APPs with the education, skills, and resources needed to provide optimal care to patients with breast cancer.

Target Audience
This activity is intended for community nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who care for patients with breast cancer. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Analyze clinical evidence supporting the use of ADCs in metastatic breast cancer
  • Explain the structural, mechanistic, and unique characteristics of ADCs that contribute to differing toxicities and adverse event profiles
  • Identify strategies for managing common and serious toxicities to effectively monitor and proactively identify signs and symptoms of serious adverse events
  • Apply knowledge of ADCs, clinical evidence, and guidelines to real-world patient case scenarios

The APP’s Guide to Patient-Centered Management of BTK Inhibitor Therapy in Lymphoma

Goal Statement
This activity aims to equip oncology APPs with the education, skills, and resources needed to provide optimal care to patients with B-cell lymphomas who are receiving or are eligible for BTK inhibitor therapy. 

Target Audience
This activity is intended for nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with lymphoma.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Describe how adverse event profiles and patient-specific factors influence the selection of BTK inhibitors in managing B-cell malignancies
  • Discuss the role of biomarker-driven testing in informing BTK inhibitor therapy selection and guiding risk mitigation strategies
  • Identify common patient-reported barriers to BTK inhibitor adherence and strategies—including patient education and digital health tools—to improve treatment continuity
  • Explain key eligibility criteria for clinical trials investigating novel BTK inhibitors to support patient counseling and trial referral decisions

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 5.0 contact hours, including 5.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 5.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Acknowledgement

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC.

Partners for Advancing Clinical Education (Partners) 2025
CCO 2022

Supporter

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Supported by an educational grant from Genmab US, Inc.


Optimizing CLL/SLL Care: Expert Strategies for APPs to Integrate New Targeted Therapies and Practice-Changing Evidence

Supported by an educational grant from Lilly.


The APP’s Guide to Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Supported by an educational grant from Lilly.


Maximizing Efficacy and Minimizing Toxicities with Antibody-Drug Conjugates in Breast Cancer

Supported by an educational grant from Gilead Sciences, Inc.


The APP’s Guide to Patient-Centered Management of BTK Inhibitor Therapy in Lymphoma

Supported by an educational grant from BeOne Medicines.

Lilly

Genmab US, Inc.

Gilead Sciences, Inc.

BeOne Medicines

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.